LATS1, active, GST tagged human, PRECISIO, recombinant, expressed in baculovirus infected Sf9 cells, >=70% (SDS-PAGE), buffered aqueous glycerol solution

Code: srp5317-10ug D2-231

Not available outside of the UK & Ireland.

General description

LATS1 is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis ...


read more

Your Price
$517.74 10UG

Not available outside of the UK & Ireland.

General description

LATS1 is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis which is phosphorylated in a cell-cycle dependent manner. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity which indicating a role as a negative regulator of CDC2/cyclin A and the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. LATS1 act as a tumor suppressor and play an important role in the development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.

Legal Information

PRECISIO is a registered trademark of Sigma-Aldrich Co. LLC

Physical form

Supplied in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, 25% glycerol.

Preparation Note

After opening, aliquot into smaller quantities and store at -70 °C. Avoid repeating handling and multiple freeze/thaw cycles.

assay≥70% (SDS-PAGE)
formbuffered aqueous glycerol solution
Gene Informationhuman ... LATS1(9113)
mol wt~95 kDa
NCBI accession no.NM_004690
product linePRECISIO®
recombinantexpressed in baculovirus infected Sf9 cells
shipped indry ice
specific activity1.1-1.7 nmol/min·mg
storage temp.−70°C
This product has met the following criteria: